Article | March 25, 2021

Hybrid Bayesian And Frequentist Clinical Trial Designs

Source: Cytel

By Yannis Jemiai, Natalia Muhlemann , Rajat Mukherjee , Pantelis Vlachos , Apurva Bhingare , Yuan Ji

medical data iStock-1250153388.jpg

Most people know that clinical drug discovery is usually conducted using either Frequentist or Bayesian methods. These two statistical paradigms have enjoyed a degree of competition historically, with some statisticians tauting the statistical rigor of Frequentist designs and others the intuitiveness and flexibility of Bayesian clinical trials. Recently, though, a number of hybrid methods have arisen, that leverage the benefits of both paradigms for singularly powerful clinical trials. There are benefits of these combined methods.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: